Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2012

View Archived Issues

Tenascin-C evaluated as a marker of isolated noncompaction cardiomyopathy

DNA decoy to prevent postsurgical pain shows promising preclinical toxicity profile

Preclinical data support clinical testing of new antiarrhythmic drug

Theravance product shows strong antinociceptive activity across a range of pain models

Jakavi approved in Europe

European Commission approves Zinforo

Novel agent is active against West Nile virus and other flaviviruses / News in Context

Bristol-Myers Squibb presents in vivo results on new Trk inhibitors

New potential cancer therapies developed at U.S. university

Genmab designs novel CD74-directed immunotherapies

Novel candidate HIV medicines presented by Bristol-Myers Squibb

Scientists in U.S. disclose novel HDAC inhibitors

Boehringer Ingelheim Pharma patents new PI3K-alpha inhibitors

New MDR efflux pump inhibitors synthesized in France

Esperance advances phase II trial in ovarian cancer

New assay to measure testosterone obtains CE mark

FDA committee to discuss Heplisav BLA

Biomarker has prognostic value in patients with diabetes and coronary artery disease

Cangene strengthens biodefense work

Resverlogix reports topline results from SUSTAIN study

Health Canada approves Treanda

Altheus Therapeutics kicks off phase II trial in ulcerative colitis

Novelos Therapeutics developing optical imaging agent for use in cancer

First patient enrolled in phase IIa AEZS-130 study

CE Mark approval for Elixir Medical stent

Pristine Solutions completes acquisition

Promising phase IIa data reported on Archexin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...